Want to see SNDX full AI Analyst Report?
Syndax Pharmaceuticals (SNDX) Stock Statistics & Valuation Metrics
Total Valuation
Syndax Pharmaceuticals has a market cap or net worth of $940.80M. The enterprise value is $1.85B.
- Market Cap
- $940.80M
- Enterprise Value
- $1.85B
Share Statistics
Syndax Pharmaceuticals has 90,028,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 90,028,260
- Owned by Insiders
- 1.59%
- Owned by Institutions
- 35.68%
Financial Efficiency
Syndax Pharmaceuticals’s return on equity (ROE) is -4.42 and return on invested capital (ROIC) is -66.60%.
- Return on Equity (ROE)
- -4.42
- Return on Assets (ROA)
- -0.54
- Return on Invested Capital (ROIC)
- -66.60%
- Return on Capital Employed (ROCE)
- -0.67
- Revenue Per Employee
- 578.36K
- Profits Per Employee
- -957.79K
- Employee Count
- 298
- Asset Turnover
- 0.33
- Inventory Turnover
- 0.21
Valuation Ratios
The current PE Ratio of Syndax Pharmaceuticals is -3.95. Syndax Pharmaceuticals’s PEG ratio is -0.09.
- PE Ratio
- -3.95
- PS Ratio
- 2.91
- PB Ratio
- -48.97
- Price to FCF
- -4.75
- Price to Operating Cash Flow
- -4.74
- PEG Ratio
- -0.09
Income Statement
In the last 12 months, Syndax Pharmaceuticals had revenue of 172.35M and earned -285.42M in profits. Earnings per share was -3.29.
- Revenue
- 172.35M
- Gross Profit
- 165.38M
- Operating Income
- -273.08M
- Pretax Income
- -285.42M
- Net Income
- -285.42M
- EBITDA
- -251.63M
- Earnings Per Share (EPS)
- -3.29
Cash Flow
In the last 12 months, operating cash flow was -177.36M and capital expenditures -96,000, giving a free cash flow of -177.46M billion.
- Operating Cash Flow
- -177.36M
- Free Cash Flow
- -177.46M
- Free Cash Flow per Share
- -1.98
Dividends & Yields
Syndax Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.94%
- Earnings Yield
- -24.78%
Stock Price Statistics
- Beta
- 1.14
- 52-Week Price Change
- -37.95%
- 50-Day Moving Average
- 16.96
- 200-Day Moving Average
- 20.20
- Relative Strength Index (RSI)
- 24.61
- Average Volume (3m)
- 2.28M
Important Dates
Syndax Pharmaceuticals upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Syndax Pharmaceuticals as a current ratio of 4.40, with Debt / Equity ratio of 536.10%
- Current Ratio
- 4.40
- Quick Ratio
- 4.12
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- -0.84
- Interest Coverage Ratio
- -8.08
Taxes
In the past 12 months, Syndax Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Syndax Pharmaceuticals EV to EBITDA ratio is -10.91, with an EV/FCF ratio of -7.33.
- EV to Sales
- 4.50
- EV to EBITDA
- -10.91
- EV to Free Cash Flow
- -7.33
- EV to Operating Cash Flow
- -7.34
Balance Sheet
Syndax Pharmaceuticals has $427.10M in cash and marketable securities with $589.41M in debt, giving a net cash position of -$162.31M billion.
- Cash & Marketable Securities
- $427.10M
- Total Debt
- $589.41M
- Net Cash
- -$162.31M
- Net Cash Per Share
- -$1.80
- Tangible Book Value Per Share
- -$0.19
Margins
Gross margin is 93.69%, with operating margin of -61.72%, and net profit margin of -72.38%.
- Gross Margin
- 93.69%
- Operating Margin
- -61.72%
- Pretax Margin
- -72.38%
- Net Profit Margin
- -72.38%
- EBITDA Margin
- -41.21%
- EBIT Margin
- -41.21%
Analyst Forecast
The average price target for Syndax Pharmaceuticals is $37.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $37.38
- Price Target Upside
- 298.88% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- 159.68%
- EPS Growth Forecast
- 34.52%
Scores
- Smart Score
- 7
- AI Score
- 50
